Human Milk Oligosaccharide LNnT Attenuates Colonic Barrier Dysfunction and Associated Cognitive Impairment via Modulating Sphingolipid Metabolism and Gut Microbiota
Molecules · 24.04.2026 · 31 (9) · 1410
DOI: 10.3390/molecules31091410 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 24.04.2026. Verfasst von Minghui Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang 330047, China. Hauptthemen laut MEDLINE: Sphingolipids, Gastrointestinal Microbiome, Oligosaccharides, Milk, Human. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Project of Natural Science Foundation of Jiangxi Province.
Abstract (Originalsprache)
This study focuses on Lacto-N-neotetraose (LNnT), a core component of human milk oligosaccharides. Although LNnT has been demonstrated to promote early intestinal development and maintain gut homeostasis, its protective mechanism against D-galactose-induced intestinal injury and associated cognitive impairment remains unclear. This investigation systematically examined the protective effects and underlying mechanisms of LNnT against D-gal-induced colonic damage and cognitive impairment in mice. The results demonstrated that LNnT not only significantly improved systemic physiological phenotypes and upregulated the expression of colonic tight junction proteins to repair the intestinal barrier, but also effectively enhanced learning and memory abilities in mice. Concurrently, LNnT reduced serum proinflammatory factor levels, elevated the anti-inflammatory factor IL-10, and alleviated oxidative stress. Furthermore, LNnT remodeled the gut microbiome structure by increasing microbial diversity, enhancing beneficial bacteria abundance, and promoting short-chain fatty acid production. Untargeted metabolomics analysis further revealed that LNnT corrected metabolic disturbances by regulating key sphingolipid molecules (ceramide, sphingosine, S1P) and the expression of related metabolic enzymes (ACER2, SphK2). In summary, this study suggests that LNnT mitigates intestinal injury and improves cognitive function, potentially through modulation of the gut microbiota–sphingolipid metabolism axis, although further causal validation is warranted. These findings provide a mechanistic foundation for future studies exploring its potential as a functional dietary ingredient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang 330047, China.
- Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo 315010, China.
- International Institute of Food Innovation, Nanchang University, Nanchang 330051, China.
ORCID-Profile: Hongyan Li, Zeyuan Deng, Liufeng Zheng
Förderung
- National Natural Science Foundation of China
- Key Project of Natural Science Foundation of Jiangxi Province
Zitieren
APA
Wang, M., Zhu, L., Liao, J., Bao, L., Li, H., Deng, Z., Li, J., Zheng, L., & Zhang, B. (2026). Human Milk Oligosaccharide LNnT Attenuates Colonic Barrier Dysfunction and Associated Cognitive Impairment via Modulating Sphingolipid Metabolism and Gut Microbiota. Molecules, 31(9), 1410. https://doi.org/10.3390/molecules31091410
Vancouver
Wang M, Zhu L, Liao J, Bao L, Li H, Deng Z, et al. Human Milk Oligosaccharide LNnT Attenuates Colonic Barrier Dysfunction and Associated Cognitive Impairment via Modulating Sphingolipid Metabolism and Gut Microbiota. Molecules. 2026;31(9):1410. doi:10.3390/molecules31091410
BibTeX
@article{Wang2026,
author = {Wang, Minghui and Zhu, Liuying and Liao, Jinqiang and Bao, Lulu and Li, Hongyan and Deng, Zeyuan and Li, Jing and Zheng, Liufeng and Zhang, Bing},
title = {Human Milk Oligosaccharide LNnT Attenuates Colonic Barrier Dysfunction and Associated Cognitive Impairment via Modulating Sphingolipid Metabolism and Gut Microbiota},
journal = {Molecules},
year = {2026},
volume = {31},
number = {9},
pages = {1410},
doi = {10.3390/molecules31091410}
}
EUVIMED